Personalized mRNA Vaccine Plus Immunotherapy Cuts Melanoma Recurrence by Half
TL;DR Summary
A phase 2b trial (KEYNOTE-942) shows adding the personalized mRNA vaccine intismeran to pembrolizumab after melanoma surgery reduces recurrence or death by 49% over five years. The combo also lowers distant metastasis risk by 59% and yields 92.2% overall survival versus 71.3% with pembrolizumab alone. Five-year follow-up found 68.8% cancer-free in the combo group vs 50.9% in controls. The study, conducted in the US and Australia with 107 patients in the combo arm and 50 in control, reported manageable side effects and is guiding a phase 3 trial, with Moderna and Merck funding.
- Cancer Vaccine Produces 49% Melanoma Reduction in Patients Five Years Later Good News Network
- Cancer vaccines based on mRNA advance, despite US cuts Reuters
- A personalized vaccine for melanoma cut the risk of cancer returning after five years NBC News
- Adding Intismeran to Pembrolizumab Boosts Survival in Advanced Resected Melanoma Cancer Therapy Advisor
- KEYNOTE-942 at ASCO: 5 Years With a Personalized mRNA Vaccine for Melanoma Targeted Oncology
Reading Insights
Total Reads
1
Unique Readers
17
Time Saved
42 min
vs 43 min read
Condensed
99%
8,516 → 93 words
Want the full story? Read the original article
Read on Good News Network